| Index | Recent Threads | Unanswered Threads | Who's Active | Guidelines | Search |
 |
World Community Grid Forums
Category: Completed Research
Forum: Help Conquer Cancer
Thread: Interesting News Articles About Cancer |
| No member browsing this thread |
|
Thread Status: Active Total posts in this thread: 954
|
|
| Author |
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges: 
|
http://www.medicalnewstoday.com/articles/250912.php
"Article Date: 01 Oct 2012 One Year On Herceptin For Breast Cancer Ideal Patients in early-stage HER2-positive breast cancer should remain on Herceptin (trastuzumab) treatment for one year, and not two years or six months, according to a final analysis of the Phase III HERA trial, pharmaceutical company Roche and the Breast International Group announced today. Experts say that had the trial found six months of Herceptin was better than one year, Swiss pharmaceutical giant, Roche would have lost approximately $1.5 billion in revenue from this medication. Herceptin is a breast cancer blockbuster medication with sales last year of $5.5 billion. Approximately one quarter of patients with breast cancer tumors which generate HER2, a protein which makes the disease much more aggressive, are treated with Herceptin. The latest data from the Phase III HERA trial demonstrated that two years of treatment on Herceptin made no difference to patients' disease-free survival times - how long women lived without the cancer coming back..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/articles/250926.php
"Article Date: 01 Oct 2012 A critical overview that highlights ways to prevent invasive cervical cancer was recently published in Cancer Epidemiology, Biomarkers & Prevention. Anna R. Giuliano, Ph.D., director of Moffitt's Center for Infection Research in Cancer and senior member of the Cancer Epidemiology Department, explained: "The good news is that over the past several decades, the incidence of invasive cervical cancer has declined dramatically. The bad news is that 60 percent of invasive cervical cancers occur in women who are members of underserved racial or ethnic minorities, in women residing in rural areas or living in poverty." The number of invasive cervical cancer cases has decreased 75% since the 1940s. Partly due to the increased extensive use of the Pap smear, a team from Moffitt Cancer Center, University of South Florida, and The Ohio State University, explained, rates have declined from 14.8 per 100,000 females in 1975, to 6.6 per 100,000 in 2008. Today, the incidence of invasive cervical cancer differs by race geography, ethnicity and socioeconomic status. The highest rate is found among Hispanics (10.4 per 100,000). The number of cases is three times higher among blacks 85 and older than white females of the same ages..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/releases/250887.php
"Article Date: 02 Oct 2012 The Challenges Of Cancer Prevention: Myths And Misunderstandings Hamper Prevention Efforts New insights on the global fight to prevent cancers were presented during the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. The studies highlight the challenges of overcoming misunderstandings about how important lifestyle factors are in reducing cancer risk. "These studies highlight the fact that a large proportion of the European population does not particularly like the idea of 'self-responsibility' for personal cancer prevention - that is, changing their habits and lifestyle accordingly. Rather, they blame genetics and society for getting cancer," said Prof Hans-Jorg Senn, St. Gallen, Switzerland, Chair of the ESMO Cancer Prevention Faculty. "Increasing awareness of the importance of primary cancer prevention is an enormous health-political issue for the future," Prof Senn said. "If we do not become more successful in truly and significantly lowering the incidence of major cancer types, such as gastrointestinal and breast cancer in our ageing society, we will wind up with drastically increasing financial burdens for ever-more active treatment and care, besides the projected losses in working capacity and the accompanying burdens of human suffering."... |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/releases/250904.php
"Article Date: 02 Oct 2012 Key Mechanism Discovered For Controlling The Body's Inflammatory Response Researchers at Queen Mary, University of London have discovered how a key molecule controls the body's inflammatory responses. The molecule, known as p110delta, fine-tunes inflammation to avoid excessive reactions that can damage the organism. The findings, published in Nature Immunology, could be exploited in vaccine development and new cancer therapies. A healthy immune system reacts to danger signals - from microorganisms such as bacteria and viruses, or from the body's own rogue cells, such as cancer cells. This tightly controlled reaction starts with an inflammatory phase that alerts and activates the body to react against the danger signals. Once the danger has been cleared, it is critical that the body's inflammatory phase is shut down to avoid overreaction...." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/releases/250913.php
"Article Date: 02 Oct 2012 Investigational Brain Cancer Vaccine To Be Tested In Phase I Roswell Park Study A new clinical research study at Roswell Park Cancer Institute (RPCI) will test a first-of-its-kind cancer "vaccine" that may prove effective against many forms of solid-tumor cancers. The vaccine, to be investigated in a trial involving patients with brain cancer, generates an immune response that appears to put the target molecule, the cancer survival protein survivin, into a bind it can't escape..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/releases/250923.php
"Article Date: 02 Oct 2012 Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it is in late stage discussions with medical centers in the U.S. and Europe to proceed with a Phase I/II clinical trial with the Company's third major product line, DCVax®-Direct, for all types of solid tumor cancers (i.e., cancers in any tissues). The Company previously received FDA approval of the clinical trial. DCVax®-Direct offers a potential new treatment option for the wide range of clinical situations in which patients' tumors are considered "inoperable" because the patient has multiple tumors, or their tumor cannot be completely removed, or the surgery would cause undue damage to the patient and impair their quality of life. A large number of patients with a variety of cancer types (including lung, colon, pancreatic, liver, ovarian, head and neck, and others) are faced with this situation, because their tumors are already locally advanced or have begun to metastasize by the time symptoms develop and the patients seek treatment. For these patients, the outlook today is bleak and survival remains quite limited..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/articles/251094.php
"Article Date: 04 Oct 2012 New Treatment And Hope For Ovarian Cancer Patients Ovarian cancer can be treated by a newly discovered type of drug that reduces the number of doses the patients need to take, and is also effective for those whose cancer has become drug-resistant. The treatment was discovered by a team at USC and has been tested on mice tumors and on ovarian cancer cells. The finding was published in the Proceedings of the National Academy of Sciences (PNAS). "We need a new generation of drugs," revealed Shili Xu, a USC graduate student and leading author. "We need to overcome the drug-resistance issue." After analyzing nearly 10,000 chemical compounds on cancer cells, the new drug, a member of a recently developed kind of cytotoxic agents abbreviated as PACMA, was developed in the lab of Nouri Neamati, professor of pharmacology and pharmaceutical sciences at the USC School of Pharmacy..." |
||
|
|
Michael2901
Veteran Cruncher Joined: Feb 6, 2009 Post Count: 586 Status: Offline Project Badges:
|
http://www.medicalnewstoday.com/articles/251087.php
"Article Date: 03 Oct 2012 Tanning Beds Cause 170,000 Skin Cancers In USA Annually Indoor tanning increases the risk of developing melanoma skin cancer, researchers reported in the BMJ (British Medical Journal) today. Tanning bed users who are exposed before they are twenty-five years old are especially vulnerable to developing basal cell carcinoma and squamous cell carcinoma, the authors added. Tanning salons are very popular in Western Europe and North America. A report published in Archives of Dermatology in December 2010 estimated that 18.1% of women and 6.3% of men in America use tanning beds regularly..." |
||
|
|
pcwr
Ace Cruncher England Joined: Sep 17, 2005 Post Count: 10903 Status: Offline Project Badges:
|
----------------------------------------  |
||
|
|
Former Member
Cruncher Joined: May 22, 2018 Post Count: 0 Status: Offline |
One Drug to Shrink All Tumors
Science magazine is reporting that researchers have found "a single drug that can shrink or cure human breast, ovary, colon, bladder, brain, liver, and prostate tumors that have been transplanted into mice. http://news.sciencemag.org/sciencenow/2012/03...nk-all-tumors.html?ref=hp |
||
|
|
|